GlassScriptPhysician profile
Raquel R Vaughan
NPI 1407958382
$6,194.41
in general payments reported to CMS, 2019-2025
32 companies · $1,743 in 2025
The $1,743 reported for 2025 was more than what 95% of Acute Care (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $137).
See the full distribution for Acute Care (Clinical Nurse Specialist)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $740 · 2022: $1,104 · 2023: $1,125 · 2024: $1,482 · 2025: $1,743.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,350.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,349.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $545.43 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $534.42 | 2021-2025 | Farxiga, Wainua, Lokelma |
| Philips North America LLC | $531.33 | 2022-2025 | (Cm9) Amb Mon & Diag Und, Ambulatory Monitoring & Diagnostics Undivided, Mcot |
| Novartis Pharmaceuticals Corporation | $462.65 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $433.16 | 2021-2024 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $424.76 | 2021-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $415.03 | 2021-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $340.31 | 2022-2025 | Camzyos, Eliquis |
| Amgen INC. | $300.49 | 2021-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $277.72 | 2022-2025 | Watchman Flx, Vigilant X4 Crt-D |
| Medtronic, INC. | $251.63 | 2021-2025 | Cobalt Dr Mri Surescan |
| Novo Nordisk INC | $211.44 | 2021-2025 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $205.20 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $193.55 | 2022-2023 | |
| Ethicon US, LLC | $170.67 | 2025 | Harmonic |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $149.90 | 2025 | Amvuttra |
| Abbott Laboratories | $145.08 | 2021-2025 | Jot Dx |
| Irhythm Technologies, INC. | $97.90 | 2022-2023 | Zio Xt Patch |
| Esperion Therapeutics, INC. | $80.97 | 2021-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $65.81 | 2022-2023 | Optimizer |
| Regeneron Healthcare Solutions, INC. | $47.90 | 2025 | Evkeeza |
| Ionis Pharmaceuticals, INC. | $47.00 | 2025 | Tryngolza |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $45.23 | 2024-2025 | Lifevest |
| Scpharmaceuticals INC. | $32.73 | 2024 | |
| Bridgebio Pharma, INC. | $30.12 | 2025 | Attruby |
| Cvrx, INC. | $29.53 | 2022-2025 | Barostim Neo System |
| Terumo Medical Corporation | $29.26 | 2024 | Glidewire |
| Atricure, INC. | $27.88 | 2021-2022 | |
| Amarin Pharma, INC. | $21.05 | 2021 | |
| Chiesi USA, INC. | $18.44 | 2022 | |
| Lexicon Pharmaceuticals, INC. | $14.30 | 2024 | |
| Heartflow, INC. | $13.52 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raquel Vaughan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.